Synribo approved to treat rare leukemia
(HealthDay)—Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat a rare blood and bone marrow disease called chronic myelogenous leukemia (CML).
Oct 26, 2012
Archive: 26/10/2012
Trial finds benefits to using radial versus femoral access for primary angioplasty in heart attack patients
OCTOBER 26, 2012 – A study found several benefits in using the radial artery in the arm as the entry point for angioplasty or percutaneous coronary intervention (PCI) compared to the femoral artery in the leg. Results of ...
Oct 26, 2012
Models developed from the PLCO may help identify at-risk patients for adverse smoking outcomes
Risk prediction models developed from an ancillary study of the Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCO) may be useful in the public health sector for identifying individuals who are at risk for ...
Oct 26, 2012
Immune system fighters speak in patterns of proteins, prefer squishy partners
When talking to the key immune system fighters known as T-cells, it helps to speak their language. Now researchers from Columbia University in New York, N.Y., and the University of Pennsylvania in Philadelphia have discovered ...
Oct 26, 2012
New clues to how the brain and body communicate to regulate weight
Maintaining a healthy body weight may be difficult for many people, but it's reassuring to know that our brains and bodies are wired to work together to do just that—in essence, to achieve a phenomenon known as energy balance, ...
Oct 26, 2012
